Taysha Gene Therapies, Inc.

NasdaqGS:TSHA Rapport sur les actions

Capitalisation boursière : US$313.6m

Taysha Gene Therapies Gestion

Gestion contrôle des critères 3/4

Taysha Gene Therapies' CEO is Sean Nolan, appointed in Dec 2022, has a tenure of 1.92 years. total yearly compensation is $1.52M, comprised of 39.4% salary and 60.6% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $1.79K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Informations clés

Sean Nolan

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG39.4%
Durée du mandat du directeur général1.9yrs
Propriété du PDG0.0006%
Durée moyenne d'occupation des postes de direction1.9yrs
Durée moyenne du mandat des membres du conseil d'administration3.8yrs

Mises à jour récentes de la gestion

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20

Taysha: Produces Solid Data But Has Abandoned Programs

Feb 06

Taysha Gene Therapies Gets A 'Thumbs Up'

Mar 07

Analyse de la rémunération des PDG

Comment la rémunération de Sean Nolan a-t-elle évolué par rapport aux bénéfices de Taysha Gene Therapies?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$118m

Dec 31 2023US$2mUS$600k

-US$112m

Sep 30 2023n/an/a

-US$214m

Jun 30 2023n/an/a

-US$124m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$2mUS$25k

-US$166m

Sep 30 2022n/an/a

-US$161m

Jun 30 2022n/an/a

-US$186m

Mar 31 2022n/an/a

-US$193m

Dec 31 2021US$321kn/a

-US$175m

Sep 30 2021n/an/a

-US$142m

Jun 30 2021n/an/a

-US$106m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$457kn/a

-US$60m

Rémunération vs marché: Sean's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD2.42M).

Rémunération et revenus: Sean's compensation has been consistent with company performance over the past year.

PDG

Sean Nolan (56 yo)

1.9yrs

Titularisation

US$1,522,515

Compensation

Mr. Sean P. Nolan serves as Executive Chairman of Jaguar Gene Therapy, LLC. Mr. Nolan has been Chairman of the board at Taysha Gene Therapies, Inc since March 2020 and serves as its Chief Executive Officer...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Sean Nolan
CEO & Chairman1.9yrsUS$1.52m0.00057%
$ 1.8k
Sukumar Nagendran
President1.9yrsUS$1.25m0.017%
$ 52.4k
Kamran Alam
CFO & Corporate Secretary4.3yrsUS$975.40k0.077%
$ 242.2k
Hayleigh Collins
Director of Corporate Communications & Investor Relationsno datapas de donnéespas de données
Tracy Porter
Chief People Officer3.8yrspas de donnéespas de données
Frederick Porter
Chief of Staff & Technical Operations Officer1.8yrspas de donnéespas de données
Emily McGinnis
Chief Patient & External Affairs Officer and Endpoint & Outcome Development Leadno datapas de donnéespas de données
Sean McAuliffe
Chief Business Officerno datapas de donnéespas de données
Steven Gray
Chief Scientific Advisor of UT Southwestern Gene Therapy Programno datapas de donnéespas de données
Berge Minassian
Chief Medical Advisor of UT Southwestern Gene Therapy Programno datapas de donnéespas de données
Rumana Haque-Ahmed
Chief Regulatory Officerno datapas de donnéespas de données
Meredith Schultz
Chief Medical Officerless than a yearpas de donnéespas de données

1.9yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: TSHA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Sean Nolan
CEO & Chairman4.7yrsUS$1.52m0.00057%
$ 1.8k
Sukumar Nagendran
President4.3yrsUS$1.25m0.017%
$ 52.4k
Phillip Donenberg
Independent Director4.3yrsUS$73.82k0.056%
$ 174.6k
Sean Stalfort
Independent Director1.4yrsUS$35.09k0.94%
$ 3.0m
Paul Manning
Board Observer1.4yrsUS$22.81k12.12%
$ 38.0m
Wendy Chung
Independent Scientific Advisory Board3.8yrspas de donnéespas de données
Deborah Bilder
Independent Scientific Advisory Board3.8yrspas de donnéespas de données
David Dimmock
Independent Scientific Advisory Board3.8yrspas de donnéespas de données
Laura Sepp-Lorenzino
Independent Director4yrsUS$76.90k0%
$ 0
Alison Long
Independent Directorless than a yearUS$77.96k0%
$ 0
Gerald Lipshutz
Independent Scientific Advisory Board3.8yrspas de donnéespas de données
Benedikt Schoser
Member of Independent Scientific Advisory Board3.1yrspas de donnéespas de données

3.8yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: TSHA's board of directors are considered experienced (3.8 years average tenure).